The antitrust revied led to Senate and Congress headings, in addition to the FTC's 8-month antitrust review. As the review looked to move in Express Scripts favor, some legislators stepped up their opposition to the deal.
In February, Sen. Herb Kohl (D., Wisc.), chairman of the Senate Antitrust Subcommittee, sent a 6-page letter to the FTC outlining potential pitfalls to the merger, including possible cost increases for corporate, union and government health insurance plans to go with competition concerns.
Nevertheless, March regulatory filings by Medco and Express Scripts indicated that both companies expected deal approval as early as April 2. The filing also noted the potential for divestitures, "subject to satisfaction or waiver of the remaining closing conditions."
Those expectations, and a confidence that the deal would close in the first half of 2012 proved to be accurate. "Our merger is exactly what the country needs now," George Paz, chief executive of Express Scripts, said in a statement. "It represents the next chapter of our mission to lower costs, drive out waste in health care and improve patient health."In a statement the FTC officials voting in favor of the merger said that the review, "revealed a competitive market for PBM services characterized by numerous, vigorous competitors who are expanding and winning business from traditional market leaders... [T]he market today is not conducive to coordinated interaction, and there is little risk of the merged company exercising monopsony power." The dissenting vote from although Commissioner Julie Brill, who described the merger as an industry "game changer" that creates a "merger to duopoly" between the merged companies and CVS Caremark (CVS), "with few efficiencies and high entry barriers - something no court has ever approved." Though antitrust risks remain, investor and analyst expectations signal that Monday's approval was key. The merger is still subject to antitrust lawsuits filed by the The National Association of Chain Drug Stores and the National Community Pharmacists Association in late March and potential litigation by state attorney generals. However, share prices and analyst comments signal that those inquiries are unlikely to halt the deal after the FTC's approval. "In relation to the retail drug association lawsuit filed late last week, our consultants believe it is unlikely that a judge would provide a restraining order on the merger close for private sector," wrote UBS analyst Steven Valiquette in a Monday note reiterating a "buy" rating and $68 price target on Express Scripts shares. Overall, analysts polled by Bloomberg give Express Scripts shares a price target of $60.93 on 21 "buy" ratings and two "holds." For more on the Express Scripts and Medco merger see why PBM's could be sandbaggin deal synergies. See why Rite Aid earnings overtake deal rumors for more on M&A in the sector. -- Written by Antoine Gara in New York
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV